netFormulary Berkshire West NHS NHS
Royal Berkshire NHS Foundation Trust
Berkshire Healthcare NHS Foundation Trust
Berkshire West Clinical Commissioning Group
 
 Search
 Formulary Chapter 11: Eye - Full Chapter
Notes:
This formulary is used by multiple organisations. There may be some instances where an item is on the formulary for one organisation but not the others. To help distinguish between each organisation, text will be colour coded, i.e. information relating to the Royal Berkshire NHS Foundation Trust will be in blue and Berkshire Healthcare NHS Foundation Trust will be in purple. Please ensure you read all information detailed under a drug.   
Chapter Links...
 Details...
11.08.02  Expand sub section  Ocular diagnostic and peri-operative preparations and photodynamic treatment
11.08.02  Expand sub section  Ocular diagnostic preparations
11.08.02  Expand sub section  Ocular peri-operative drugs
11.08.02  Expand sub section  Subfoveal choroidal neovascularisation
Aflibercept intravitreal injection (Eylea)
View adult BNF View SPC online View childrens BNF  Track Changes
First Choice
Red
High Cost Medicine
note Commissioning requirements for funding may apply. Please contact pharmacy for details prior to prescribing this item.

First choice anti VEGF agent for treating Wet Age Related Macular Degeneration

Royal Berkshire NHS Foundation Trust >> Formulary Item intravitreal injection
Restricted Item ONLY in line with NICE TA - link below

 
Bevacizumab intravitreal injection (Avastin)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine
note  Commissioning requirements for funding may apply. Please contact pharmacy for details prior to prescribing this item.

Royal Berkshire NHS Foundation Trust >> Formulary Item intravitreal injection
 
   
Ranibizumab (Lucentis)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
High Cost Medicine

note  Commissioning requirements for funding may apply. Please contact pharmacy for details prior to prescribing this item.

Royal Berkshire NHS Foundation Trust >> Formulary Item intravitreal injection in line with NICE TA (links below)
- wet age related macular oedema TA 155
- diabetic macular oedema TA 274
- choroidal neovascularisation TA 298
- retinal vein occlusion TA 283

 
Link  NICE TA 283 - Ranibizumab for treating visual impairment caused by macular oedema secondary to retinal vein occlusion
Link  NICE TA 298 - Ranibizumab for treating choroidal neovascularisation associated with pathological myopia
Link  NICE TA155: Ranibizumab and pegaptanib for the treatment of age-related macular degeneration
Link  NICE TA274 - Ranibizumab for the treatment of diabetic macular oedema
   
Verteporfin (Visudyne)
View adult BNF View SPC online View childrens BNF  Track Changes
Formulary
Red
Royal Berkshire NHS Foundation Trust >> Formulary Item injection for use in photodynamic therapy (in line with NICE TA)
 
Link  NICE TA 68 - Guidance on the use of photodynamic therapy for age-related macular degeneration
   
 ....
 Non Formulary Items
Pegaptanib Sodium  (Macugen)

View adult BNF View SPC online View childrens BNF Track Changes
Non Formulary
Brown
Royal Berkshire NHS Foundation Trust >> NON - Formulary Item - contact pharmacy for advice
Link  London New Drugs review (May 2006)
Link  New medicines profile for Pegaptanib (Jun 06)
Link  NICE guidance on pegaptanib in AMD (August 2008)
 
  
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Amber

Medicines that should be initiated or recommended by a specialist for continuation in primary care. The specialist must notify the primary care provider that the prescribing responsibility has been transferred. Where applicable, shared care protocols will be agreed and must be adhered to. The shared care protocol must have been agreed by the relevant secondary care trust Drugs and Therapeutics Committee(s)(DTC) and approved by Berkshire West APC.   

Brown

Drugs that have been reviewed and not recommended for prescribing. These drugs are not considered a cost effective use of scarce NHS resources. There may be individual patient specific or clinical reasons why a drug deemed low priority may be suitable for a particular patient. This is for the GP to condsider, weighing up the reasons against his/her allocated CCG budget. Where the decision is made to prescribe a low priority drug, detailed documentation must be included within the patients' notes for audit purposes. *Please note that low priority drug requests are unsuitable for the Case Review Committee and therefore should not be sent to this committee.   

Green

Medicines suitable for routine use and can be prescribed within primary care within their licensed indication in accordance with the BNF or other recognised national formulary. Primary care prescribers take full responsibility for prescribing  

Red

Medicines which should be prescribed by specialists only  

netFormulary